RET and non-small cell lung carcinoma: This mutation leads to non-ligand-dependent activation and abnormal expression of RET, forming a high level of active RET oncoprotein and multi-kinase signaling center, promoting the occurrence of NSCLC and being considered a target for the treatment of NSCLC [9].